Free Trial
NASDAQ:SCNI

Scinai Immunotherapeutics Q4 2023 Earnings Report

Scinai Immunotherapeutics logo
$1.60 0.00 (0.00%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$1.59 -0.01 (-0.56%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scinai Immunotherapeutics EPS Results

Actual EPS
-$240.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scinai Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scinai Immunotherapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Scinai Immunotherapeutics' Q2 2025 earnings is scheduled for Thursday, August 21, 2025, with a conference call scheduled on Tuesday, August 19, 2025 at 11:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Scinai Immunotherapeutics Earnings Headlines

A new rule goes live in July — and the banks are quietly crushing it
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Scinai Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics (NASDAQ:SCNI) Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

View Scinai Immunotherapeutics Profile

More Earnings Resources from MarketBeat